



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/53, 33/543, C12P 21/06, C12N 5/00, A01N 45/00, C07K 1/00, 16/00		A1	(11) International Publication Number: WO 97/16728 (43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/US96/17462 (22) International Filing Date: 28 October 1996 (28.10.96)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/556,823 2 November 1995 (02.11.95) US		Published <i>With international search report.</i>	
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).			
(72) Inventors: PRUSINER, Stanley, B.; 400 Pacheco Street, San Francisco, CA 94116 (US). KANEKO, Kiyotschi; 1806 15th Avenue, San Francisco, CA 94122 (US). COHEN, Fred, E.; 767 Road Island Street, San Francisco, CA 94107 (US).			
(74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).			

(54) Title: FORMATION AND USE OF PRION PROTEIN (PrP) COMPLEXES

(57) Abstract

Prion protein (PrP) peptides having at least one α -helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrP^c) to form a complex having characteristics of the scrapie isoform (PrP^{Sc}). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrP^c are disclosed, as well as methods for assaying PrP^{Sc}.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Formation and Use of Prion Protein (PrP) ComplexesGovernment Rights

5 The United States Government may have certain rights in this application pursuant to Grant Nos. AG10770, AG08967, NS07219, NS14069, NS22786 and AG021732, awarded by the National Institutes of Health.

10 Field of the Invention

This invention relates to assays for testing drugs by using natural and synthetic prion protein peptides.

Background of the Invention

15 Prions are infectious pathogens that cause central nervous system spongiform encephalopathies in humans and animals. Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of 20 prion protein. Further, a prion which infects one species of animal (e.g., a human) will not infect another (e.g., a mouse).

A major step in the study of prions and the diseases that they cause was the discovery and purification of a 25 protein designated prion protein ("PrP") (Bolton et al. (1982) Science 218:1309-11; Prusiner et al. (1982) Biochemistry 21:6942-50; McKinley et al. (1983) Cell 35:57-62). Complete prion protein-encoding genes have since been cloned, sequenced and expressed in transgenic 30 animals. PrP^c is encoded by a single-copy host gene (Basler et al. (1986) Cell 46:417-28) and is normally found at the outer surface of neurons. Prion diseases are accompanied by the conversion of PrP^c into a modified form called PrP^{sc}. However, the actual biological or 35 physiological function of PrP^c is not known.

The scrapie isoform of the prion protein (PrP^{sc}) is necessary for both the transmission and pathogenesis of

the transmissible neurodegenerative diseases of animals and humans. See Prusiner (1991) *Science* 252:1515-1522). The most common prion diseases of animals are scrapie of sheep and goats and bovine spongiform encephalopathy (BSE) of cattle (Wilesmith & Wells (1991) *Microbiol. Immunol.* 172:21-38). Four prion diseases of humans have been identified: (1) kuru, (2) Creutzfeldt-Jakob Disease (CJD), (3) Gerstmann-Sträussler-Scheinker Disease (GSS), and (4) fatal familial insomnia (FFI) (Gajdusek (1977) *Science* 197:943-960; Medori et al. (1992) *N. Engl. J. Med.* 326:444-449). The presentation of human prion diseases as sporadic, genetic and infectious illnesses initially posed a conundrum which has been explained by the cellular genetic origin of PrP.

Most CJD cases are sporadic, but about 10-15% are inherited as autosomal dominant disorders that are caused by mutations in the human PrP gene (Hsiao et al. (1990) *Neurology* 40:1820-1827; Goldfarb et al. (1992) *Science* 258:806-808; Kitamoto et al. (1994) *Proc. R. Soc. Lond.* (In press). Iatrogenic CJD has been caused by human growth hormone derived from cadaveric pituitaries as well as dura mater grafts (Brown et al. (1992) *Lancet* 340:24-27). Despite numerous attempts to link CJD to an infectious source such as the consumption of scrapie infected sheep meat, none has been identified to date (Harries-Jones et al. (1988) *J. Neurol. Neurosurg. Psychiatry* 51:1113-1119) except in cases of iatrogenically induced disease. On the other hand, kuru, which for many decades devastated the Fore and neighboring tribes of the New Guinea highlands, is believed to have been spread by infection during ritualistic cannibalism (Alpers (1979) Slow Transmissible Diseases of the Nervous System, Vol. 1, S.B. Prusiner and W.J. Hadlow, eds. (New York: Academic Press), pp. 66-90). The initial transmission of CJD to experimental primates has a rich history beginning with William Hadlow's recognition of the similarity between kuru and

scrapie. In 1959, Hadlow suggested that extracts prepared from patients dying of kuru be inoculated into non-human primates and that the animals be observed for disease that was predicted to occur after a prolonged 5 incubation period (Hadlow (1959) Lancet 2:289-290). Seven years later, Gajdusek, Gibbs and Alpers demonstrated the transmissibility of kuru to chimpanzees after incubation periods ranging from 18 to 21 months (Gajdusek et al. (1966) Nature 209:794-796). The 10 similarity of the neuropathology of kuru with that of CJD (Klatzo et al. (1959) Lab Invest. 8:799-847) prompted similar experiments with chimpanzees and transmissions of disease were reported in 1968 (Gibbs et al. (1968) Science 161:388-389). Over the last 25 years, about 300 15 cases of CJD, kuru and GSS have been transmitted to a variety of apes and monkeys.

The expense, scarcity and often perceived inhumanity of such experiments have restricted this work and thus limited the accumulation of knowledge. While the most 20 reliable transmission data has been said to emanate from studies using non-human primates, some cases of human prion disease have been transmitted to rodents but apparently with less regularity (Gibbs et al. (1979) Slow Transmissible Diseases of the Nervous System, Vol. 2, 25 S.B. Prusiner and W.J. Hadlow, eds. (New York: Academic Press), pp. 87-110; Tateishi et al. (1992) Prion Diseases of Humans and Animals, Prusiner, et al., eds. (London: Ellis Horwood), pp. 129-134).

The infrequent transmission of human prion disease 30 to rodents has been cited as an example of the "species barrier" first described by Pattison in his studies of passaging the scrapie agent between sheep and rodents (Pattison (1965) NINDB Monograph 2, D.C. Gajdusek, C.J. Gibbs Jr. and M.P. Alpers, eds. (Washington, D.C.: 35 U.S. Government Printing), pp. 249-257). In those investigations, the initial passage of prions from one species to another was associated with a prolonged

incubation time with only a few animals developing illness. Subsequent passage in the same species was characterized by all the animals becoming ill after greatly shortened incubation times.

5 The molecular basis for the species barrier between Syrian hamster (SHa) and mouse was shown to reside in the sequence of the PrP gene using transgenic (Tg) mice (Scott et al. (1989) *Cell* 59:847-857). SHaPrP differs from MoPrP at 16 positions out of 254 amino acid residues
10 (Basler et al. (1986) *Cell* 46:417-428; Locht et al. (1986) *Proc. Natl. Acad. Sci. USA* 83:6372-6376). Tg(SHaPrP) mice expressing SHaPrP had abbreviated incubation times when inoculated with SHa prions. When similar studies were performed with mice expressing the
15 human, or ovine PrP transgenes, the species barrier was not abrogated, i.e., the percentage of animals which became infected were unacceptably low and the incubation times were unacceptably long. Thus, it has not been possible, for example in the case of human prions, to use
20 transgenic animals (such as mice containing a PrP gene of another species) to reliably test a sample to determine if that sample is infected with prions. The seriousness of the health risk resulting from the lack of such a test is exemplified below.

25 More than 45 young adults previously treated with HGH derived from human pituitaries have developed CJD (Koch et al. (1985) *N. Engl. J. Med.* 313:731-733; Brown et al. (1992) *Lancet* 340:24-27; Fradkin et al. (1991) *JAMA* 265:880-884; Buchanan et al. (1991) *Br. Med. J.* 302:824-828). Fortunately, recombinant HGH is now used, although the seemingly remote possibility has been raised that increased expression of wild-type PrP^c stimulated by high HGH might induce prion disease (Lasmezas et al. (1993) *Biochem. Biophys. Res. Commun.* 196:1163-1169).
30 That the HGH prepared from pituitaries was contaminated with prions is supported by the transmission of prion disease to a monkey 66 months after inoculation with a
35

suspect lot of HGH (Gibbs et al. (1993) N. Engl. J. Med. 328:358-359). The long incubation times associated with prion diseases will not reveal the full extent of iatrogenic CJD for decades in thousands of people treated 5 with HGH worldwide. Iatrogenic CJD also appears to have developed in four infertile women treated with contaminated human pituitary-derived gonadotrophin hormone (Healy et al. (1993) Br. J. Med. 307:517-518; Cochius et al. (1993) Aust. N.Z. J. Med. 20:592-593; 10 Cochius et al. (1992) J. Neurol. Neurosurg. Psychiatry 55:1094-1095) as well as at least 11 patients receiving dura mater grafts (Nisbet et al. (1989) J. Am. Med. Assoc. 261:1118; Thadani et al. (1988) J. Neurosurg. 69:766-769; Willison et al. (1991) J. Neurosurg. 15 Psychiatric 54:940; Brown et al. (1992) Lancet 340:24-27).

Recently, two doctors in France were charged with involuntary manslaughter of a child who had been treated with growth hormones extracted from corpses. The child 20 developed Creutzfeldt-Jakob Disease. (See New Scientist, July 31, 1993, page 4). According to the Pasteur Institute, since 1989 there have been 24 reported cases of CJD in young people who were treated with human growth hormone between 1983 and mid-1985. Fifteen of these 25 children have died. It now appears as though hundreds of children in France have been treated with growth hormone extracted from dead bodies at the risk of developing CJD (see New Scientist, November 20, 1993, page 10).

These cases underscore the urgent need to develop 30 therapies for PrP^{Sc}-mediated disease such as CJD. Although many lines of evidence support the idea that PrP^C is converted into the modified scrapie isoform PrP^{Sc}, the conditions under which this occurs is not known. Knowledge of the conditions under which scrapie 35 infectivity is generated *de novo* would be useful in the development of assays to identify compounds able to inhibit the generation of PrP^{Sc}. Compounds able to

inhibit the *in vitro* conversion of PrP^c to PrP^{sc} could be useful for the treatment and prevention of prion-mediated diseases in animal and human subjects at risk.

Despite progress made in identifying prions, PrP genes and the like, there does not exist any assay which would be useful in assaying compounds in the treatments of diseases caused by prions. In view of the serious nature of diseases caused by prions, there exists a need for such an assay as provided by the present invention.

10

Summary of the Invention

The present invention provides assay methods using naturally occurring and synthetic prion protein peptides (PrP peptides) which induce a conformational change in PrP^c by formation of a prion protein complex exhibiting the hallmarks of the isoform PrP^{sc}, e.g., a PrP^{sc}-like complex. This assay is useful for screening compounds able to prevent the *in vitro* induction of PrP^c to the PrP^{sc}-like complex. Compounds identified by the method of the invention are candidates for the development of therapies for the treatment of PrP^{sc}-mediated diseases, e.g., compounds able to inhibit or slow the development of PrP^{sc}-mediated diseases in a subject at risk for development of a PrP^{sc}-mediated disease.

Accordingly, the invention features PrP peptides able to bind PrP^c or a PrP variant, forming a prion protein complex having one or more PrP^{sc}-like characteristics of an increased β -sheet content, diminished aqueous solubility, and/or resistance to proteolytic digestion relative to PrP^c. The PrP peptides of the invention are characterized as having at least one α -helical domain and/or forming a random coil conformation in an aqueous solution. The PrP peptides of the invention include naturally occurring, recombinant and synthetic peptides. Preferred peptides include random coil peptides having amino acid sequence of residues 90-145 (SEQ ID NO:1) of the naturally occurring

PrP protein amino acid sequence (Fig. 1) and residues 90-231 (SEQ ID NO:2) of the naturally occurring PrP^c protein. The 90-145 amino acid portion of the naturally occurring amino acid sequence includes two α -helical domains. The 5 90-231 amino acid sequence includes four α -helical domains.

The invention includes PrP peptides having minor modifications of amino acids 90-145 (SEQ ID NO:1) or 90-231 (SEQ ID NO:2), which may result in enhanced binding 10 to PrP^c and/or enhanced induction of a PrP^{sc}-like complex. In a preferred embodiment, the PrP peptide has the 90-145 amino acid sequence in which alanine at position 117 is replaced with valine (PrP peptide 90-145(A117V)). The invention further includes peptides containing deletions 15 of one or more amino acids which result in the modification of the structure of the resultant molecule without significantly altering its ability to bind PrP^c to form a prion protein complex or to induce a conformational change in PrP^c to form a PrP^{sc}-like complex.

20 The prion protein complex formed by binding of PrP peptides to PrP^c or a PrP variant is characterized by an increased β -sheet content, diminished solubility, and/or increased resistance to proteolytic digestion relative to PrP^c. The prion protein complex is a PrP^{sc}-like complex 25 which forms fibrous aggregates, sediments at 100,000 \times g for 1 h, exhibits resistance to proteolytic digestion and displays a high β -sheet content. The prion protein complex preferably contains a 20-100% increased β -sheet content relative to PrP^c; and more preferably, the prion 30 protein complex has an increased β -sheet content of about 50-100% relative to PrP^c. The insoluble prion protein complex is at least about 20% protease resistant, preferably about 45-100% protease resistant, and more preferably, about 60-100% protease resistant.

35 In one aspect, the invention features an assay method for screening compounds able to decrease or inhibit the binding of a PrP peptide to PrP^c or a PrP

variant. A test compound is contacted with a first component PrP^c or PrP variant in the presence of a second component PrP peptide, and the ability of the test compound to prevent the formation of a prion protein complex determined. The first component PrP^c may be the synthetic, naturally derived, or recombinant protein from any species source of interest, including human, mouse, hamster, bovine, or ovine. Preferably, PrP^c is the human prion protein, and more preferably, PrP^c is a recombinantly produced human prion protein. First component PrP^c also includes variants of the naturally occurring or recombinant protein. In one embodiment, the first component is the recombinant peptide having amino acid residues 90-231 of human PrP^c (SEQ ID NO:10).

15 In a related aspect, the invention features a method for screening compounds able to decrease or inhibit the induction of a prion protein complex between a first component PrP^c and a second component PrP peptide. A test compound is contacted with PrP^c in the presence of a PrP peptide, and the induction of a prion protein complex determined.

20 A test compound able to prevent or decrease PrP peptide binding to PrP^c and/or prevent or decrease induction of a prion protein complex may be useful in vivo for preventing or treating a PrP^{sc}-mediated disease, such as Creutzfeldt-Jacob Disease (CJD), Gerstmann-Sträussler-Scheinker Disease (GSS), fatal familiar insomnia (FFI), kuru, scrapies, bovine spongiform encephalopathy (BSE), and any other disease connected to 25 formation of PrP^{sc}. A test compound identified by the method of the invention as able to inhibit or decrease the *in vitro* induction of a prion protein complex can be tested in an *in vivo* model of PrP^{sc} disease for ability to 30 prevent development of a PrP^{sc} disease.

35 In another aspect, the invention features an assay for PrP^{sc}. The presence of PrP^{sc} in a sample is determined from the displacement of a PrP peptide from the prion

protein complex. In one embodiment, a prion protein complex is allowed to form between a labelled PrP peptide and PrP^c, and a test sample added. The amount of displaced peptide is determined by measuring the amount 5 of label in the supernatant fraction after centrifugation to pellet the insoluble prion protein complexes. In another embodiment, the first component PrP^c is affinity labeled and immobilized after prion protein complex formation with a second component labelled PrP peptide. 10 A test sample is added, and the amount of displaced labelled peptide is determined in the unbound phase.

In another aspect, the invention features a method for designing PrP^c transgenes with improved ability to induce prion protein complex formation. Modified PrP^c 15 molecules are generated and their ability to form prion protein complexes determined as described above. By this method, modified transgenes with improved PrP^{sc} binding can be identified for use in improved prion bioassays. Such bioassays can be optimized for each species, e.g., 20 human, bovine, ovine or porcine prions.

An important feature of the invention is that the methodology makes it possible to identify candidate compounds which prevent the *in vitro* induction of a PrP^{sc}-like complex from the PrP^c isoform.

25 An advantage of the invention is that methodology makes it possible to test candidate compounds so identified in existing *in vivo* models of PrP^{sc} diseases. Another advantage is in providing a rapid and convenient assay for PrP^{sc}.

30 These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the methods, assays, and peptides of the invention as more fully described below.

Brief Description of the Figure

Fig. 1 is the amino acid sequence for Syrian hamster PrP^c sequences 90-231 (SEQ ID NO:2) with specific differences to human PrP^c 90-231 sequence (SEQ ID NO:10).

5

Detailed Description

Before the present methods and controls are described, it is to be understood that this invention is not limited to particular methods, assays, or peptides 10 described, as such methods, assays and peptides may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will 15 be limited only by the appended claims.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods 20 and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe 25 the methods and/or materials in connection with which the publications are cited.

Definitions

The term "prion" shall mean an infectious particle 30 known to cause diseases (spongiform encephalopathies) in humans and animals. "Prion" is a contraction of the words "protein" and "infection" and the particles are comprised largely if not exclusively of PrP^{sc} molecules encoded by a PrP gene. Prions are distinct from 35 bacteria, viruses and viroids. Known prions include those which infect animals to cause scrapie, a transmissible, degenerative disease of the nervous system

of sheep and goats as well as bovine spongiform encephalopathies (BSE) or mad cow disease and feline spongiform encephalopathies of cats. Four prion diseases known to affect humans are (1) kuru, (2) Creutzfeldt-
5 Jakob Disease (CJD), (3) Gerstmann-Sträussler-Scheinker Disease (GSS), and (4) fatal familial insomnia (FFI). As used herein prion includes all forms of prions causing all or any of these diseases or others in any animals used - and in particular in humans and in domesticated
10 farm animals.

There are a number of known variants to the human PrP gene. Further, there are known polymorphisms in the human, sheep and bovine PrP genes. The following is a
15 list of such variants:

	Pathogenic Human Polymorphisms	Human Polymorphisms	Sheep	Bovine Polymorphisms
	Human Polymorphisms			
	Mutations			
5	2 octarepeat insert	Codon 129 Met/Val	Codon 171 Arg/Glu	5 or 6 octarepeats
	4 octarepeat insert	Codon 219 Gly/Lys	Codon 136 Ala/Val	
10	6 octarepeat insert			
	7 octarepeat insert			
	8 octarepeat insert			
15	9 octarepeat insert			
	Codon 102 Pro-Leu			
20	Codon 105 Pro-Leu			
	Codon 117 Ala-Val			
	Codon 145			
25	Stop			
	Codon 178 Asp-Asn			
	Codon 180			
	Val-Ile			
30	Codon 198 Phe-Ser			
	Codon 200 Glu-Lys			
	Codon 210			
35	Val-Ile			
	Codon 217 Asn-Arg			
	Codon 232 Met-Ala			
40				

As used herein, the term "PrP peptide" is broadly defined as any peptide which when contacted with naturally occurring or recombinant PrP^c or PrP variant results in the induction of a conformational change which can be identified by presence of enhanced β -sheet formation, increased insolubility, and/or increased protease resistance relative to PrP^c, e.g., having PrP^{sc} characteristics. In one embodiment, PrP peptide shall

mean a naturally occurring, recombinant, or synthetic amino acid sequence having a sequence substantially similar (e.g., 90% or greater homology) to a portion of the naturally occurring prion protein sequence having 5 residues 90-145 (SEQ ID NO:1), or a portion thereof, and able to bind PrP^c such that a prion protein complex is formed having one or more of the characteristics of PrP^{sc}. In a second embodiment, PrP peptide shall mean a naturally occurring, recombinant, or synthetic amino acid 10 sequence having a sequence substantially similar to a portion of the naturally occurring prion protein sequence having residues 90-231 (SEQ ID NO:10), or a portion thereof, and able to bind PrP^c such that a PrP^{sc}-like complex is formed. The PrP peptide is characterized as 15 having at least one α -helical domain and/or having a random coil conformation in a aqueous solution. Further, the PrP peptide may be characterized as having a conformation in aqueous solution which is substantially devoid of β -sheet conformation. The conformation of a 20 PrP peptide of the invention is determined by a number of methods known in the art, including circular dichroism (CD).

In specific embodiments, a PrP peptide of the invention is characterized as having between 1-4 α -helical domains and binding PrP^c to form a prion protein complex. In preferred embodiment, the PrP peptide has the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:10. The PrP peptide may have modifications of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:10, e.g., one or 25 more amino acid changes, one or more amino acid deletions, and/or one or more amino acid insertions, so long as it retains the characteristics of having at least one α -helical domain and/or a random coil conformation in an aqueous solution, and binding PrP^c to form a prion 30 protein complex. Preferably, the changes, deletions, 35

insertions, and the like, are in the sequence between amino acids 90-145. For example, PrP peptide 90-145 (A117V) contains the pathogenic mutation at amino acid residue 117 (alanine to valine) which causes the 5 telencephalic and ataxic forms of GSS disease.

The terms "**PrP^{Sc}-like complex**", "**prion protein complex**", or "**PrP^C/PrP peptide complex**" are used interchangeably to mean a complex formed between PrP^C and a PrP peptide which exhibits the hallmarks of the PrP^{Sc} isoform characterized by formation of an insoluble pellet 10 when centrifuged at 100,000 x g for 1 h, and/or having a high β -sheet content typical of PrP^{Sc}, and/or exhibiting resistant to proteolytic digestion. The prion protein complex is formed between first and second components. 15 A first component of the complex, PrP^C, may be a naturally occurring or recombinant PrP protein, or variant thereof. For example, in one specific embodiment, the first component PrP^C is the naturally occurring PrP^C. In another specific embodiment, the first component PrP^C is 20 a N-terminus truncated PrP^C protein having 90-231 amino acids (SEQ ID NO:10). The second component of the complex is a recombinant or synthetic PrP peptide. To form a PrP^{Sc}-like or prion protein complex, an excess of the second component, which has a random coil or α -helical conformation, is required. In specific 25 embodiments, the second component PrP peptide has an amino acid sequence selected from one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10. 30

The terms "**treatment**", "**treating**" and the like are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially 35 preventing a disease or symptom thereof and/or may be

therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease.

More specifically, "treatment" is intended to mean 5 providing a therapeutically detectable and beneficial effect on a patient suffering from a PrP-related disease.

PrP^{Sc} Formation

The formation of PrP^{Sc} is a post-translational 10 process (Borschelt et al. (1990) J. Cell Biol. 110:743-752) in which PrP^C forms a complex with PrP^{Sc} and is transformed into a second molecule of PrP^{Sc} (Prusiner et al. (1990) Cell 63:673-686). While attempts to detect a covalent change that distinguishes PrP^C from PrP^{Sc} have 15 been unsuccessful (Stahl et al. (1993) Biochemistry 32:1991-2002), spectroscopic studies demonstrated that PrP^C contains ~40% α -helix and is devoid of β -sheet (Pan et al. (1993) Proc. Natl. Acad. Sci. USA 90:10962-10966). In contrast, PrP^{Sc} has a high β -sheet content which 20 correlates with scrapie infectivity (Prusiner et al. (1983) Cell 35:349-358; Caughey et al. (1991) Biochemistry 30:7672-7680; Gasset et al. (1993) Proc. Natl. Acad. Sci. USA 90:1-5; Safar et al. (1993) J. Biol. Chem. 268:20276-20284).

25 Studies of mice expressing Syrian hamster (SHa) PrP transgenes suggest that PrP^C and PrP^{Sc} form a complex during the formation of nascent PrP^{Sc} (Prusiner et al. (1990) Cell 63:673-686). The present inventors were unable to demonstrate PrP^{Sc} production through formation 30 of such complexes by mixing purified fractions equimolar amounts of the two isoforms (Raeber et al. (1992) J. Virol. 66:6155-6163). Other investigators have demonstrated an interaction between PrP^{Sc} and PrP^C by mixing a 50-fold excess of PrP^{Sc} with labeled PrP^C (Kocisko et al. (1994) Nature 370:471-474).

Synthetic PrP peptides corresponding to regions of putative secondary structure and displaying conformational pluralism have been studied (Gasset et al. (1992) Proc. Natl. Acad. Sci. USA 89:10940-10944; Nguyen 5 et al. (1995) Biochemistry 34:4186-4192). Transgenic studies with chimeric PrP genes suggest that PrP^c and PrP^{Sc} may interact within a central domain delimited by codons 96 and 169 (Scott et al. (1992) Protein Sci. 1:986-997; Scott et al. (1993) Cell 73:979-988; Telling et al. 10 (1994) Proc. Natl. Acad. Sci. USA 91:9936-9940). The present disclosure presents the first physical evidence that PrP peptides encompassing the first two putative α -helical regions and mimicking many structural features of the two PrP isoforms, when mixed with PrP^c, induce 15 formation of a complex which is resistant to proteolytic digestion and which sediments at 100,000 x g for 1 h.

Previous work from this laboratory has shown that small PrP peptides can interact with each other to induce conformational changes (Nguyen et al. (1985) Biochemistry 20 34:4186-4192), and that a 56-residue peptide, SHa 90-145, corresponding to the N-terminus of PrP 27-30, displays multiple conformations (Zhang et al. (1995) J. Mol. Biol. 250:514-526). Example 2 below describes experiments elucidating the role of conformational form in the 25 formation of a PrP^{Sc}-like complex. Labeled SHaPrP^c was incubated with random coil or β -sheet forms of the PrP peptides SHa 90-145, SHa 109-122 and Mo 90-145, and their effect on induction of protease resistance determined. Mixtures of PrP^c and SHa 90-145 formed fibrous aggregates 30 which displayed the high β -sheet content typical of PrP^{Sc}. Unexpectedly, it was found that random coil SHa 90-145 induced protease resistance, while SHa 90-145 in the β -sheet form did not. Mo 90-145 in either the random coil or β -sheet form did not induce protease resistance when 35 incubated with SHaPrP^c.

In some experiments, *E. coli* expressed recombinant SHa 90-231 was used in place of PrP^c. The mixture of SHa 90-145 and SHa 90-231 under the same conditions which generated the PrP^{sc}-like complex between PrP^c and SHa 90-5 145 resulted in formation of an insoluble complex exhibiting protease resistance.

To localize the region in which PrP peptides interact with PrP^c, shorter peptides were examined, including the recombinant SHa 90-231 peptide. Neither H1 10 (containing residues 109-122) nor a longer version composed of residues 104-122 (104H1) induced protease resistance in PrP^c. In aqueous buffers, H1 rapidly folds into β -sheets and polymerizes (Gasset et al. (1992) Proc. Natl. Acad. Sci. USA 89:10940-10944), while 104H1 is 15 random coil (Nguyen et al. (1995) supra). Both SHa 109-141 and SHa 90-145 induced protease resistance. When the pathogenic A117V mutation causing both the telencephalic and ataxic forms of Gerstmann-Sträussler-Scheinker (GSS) disease (Dohura et al. (1989) Biochem. Biophys. Res. 20 Commun. 163:974-979; Hsiao et al. (1991) Neurology 41:681-684; Mastrianni et al. (1995) Neurology (In Press)) was substituted in the peptide, ~65% of the radiolabeled PrP^c formed sedimentable complexes. Compared with the wild-type peptide, only 30-40% of the mutant SHa 25 90-145(A117V) peptide was needed to produce equivalent amounts of protease-resistant PrP^c. When SHa 90-145 was substituted by SHa 90-231, an insoluble complex resulted which exhibited enhanced protease resistance.

The addition of 2% (w/v) Sarkosyl disrupted the 30 prion protein complexes and rendered the PrP^c sensitive to protease activity. With SHa 90-145(A117V), about 30% of the [³⁵S-]- PrP^c/PrP peptide complex exhibited protease resistance; whereas with SHa 90-145, only 10-15% was resistant.

Since the protease resistance of the PrP^c/PrP peptide complexes resembled that of PrP^{sc} (Turk et al. (1988) Eur. J. Biochem. 176:21-30; Meyer et al. (1986) Proc. Natl. Acad. Sci. USA 83:2310-2314; McKinley et al. (1991) J. Virol. 65:1440-1449) the physical properties of the PrP^c/SHa 90-145 complex was investigated by FTIR spectra analysis, CD, and electron microscopy, of SHa 90-145 and the PrP^c/SHa 90-145 complex (Example 3). Less than 10% of the [³⁵S-]PrP^c sedimented when SHaPrP^c was incubated alone, whereas ~65% of the radiolabel pelleted with the addition of SHa 90-145(A117V). The sedimented PrP^c/SHa 90-145 complex showed a substantial increase in β -sheet content compared to pelleted PrP^c.

Anti-PrP monoclonal antibodies 3F4 and 13A5 bind to SHaPrP^c within the region spanned by the SHa 90-145 peptide. 3F4 recognizes residues 109-112 (Rogers et al. (1991) J. Immunol. 147:3568-3574), and 13A5 recognizes residues 138-141 (Barry & Prusiner (1986) J. Infect. Dis. 154:518-521). The ability of these antibodies to prevent acquisition of protease resistance was examined (Example 4). Both mAbs were found to prevent the formation of protease-resistance PrP^c/SHa 90-145 complexes.

Experiments were conducted to determine if PrP^c could spontaneously become protease resistant in the absence of PrP peptides (Example 5). In the absence of SHa 90-145(A117V) approximately 1% of the PrP^c was found to be protease resistant, whereas about 30% of the PrP^c became resistant with the peptide. Experiments were conducted to determine if PrP^{sc} mixed with PrP^c might render PrP^c protease resistant. Other investigators have reported that PrP^{sc} denatured in 3 M Gdn-HCl undergoes renaturation and renders PrP^c resistant to proteolysis within 2 min of mixing (Kocisko et al. (1994) Nature 370:417-474). Since numerous attempts to renature prion infectivity from both Gdn and urea had failed (Prusiner et al. (1993) Proc.

Natl. Acad. Sci. USA 90:2793-2797), the effect of 3 M Gdn-HCl on PrP^{sc} was investigated (Example 6). Mixing denatured PrP^{sc} with PrP^c did not result in formation of protease-resistant PrP^c.

5 It is estimated that 10-15% of PrP^c mixed with non-denatured PrP^{sc} acquired protease resistance after 48 h (Example 6), in contrast to mixing with the SHa 90-145(A117V) peptide where about 30% PrP^c demonstrated protease resistance (Example 5). After incubation with 10 SHa 90-145 for 1 hr, about 35% of the [³⁵S-]PrP^c that exhibited protease resistance at 48 h was present, by 24 h, about 75% of the PrP^c was protease resistant. Experiments were unable to reproduce the report that 15 protease-resistant [³⁵S-]PrP^c was generated within 2 min after mixing with a 50-fold excess of unlabeled PrP^{sc} (Kocisko et al. (1994) Nature 370:471-474).

The interaction between PrP^c and PrP^{sc} was found to be inhibited by anti-PrP mAb 3F4, but not by 13A5 (Example 7). The possibility that this difference 20 between the two mAbs might indicate a critical role for the PrP residues in the vicinity of the 3F4 epitope, which is the N-terminus of the H1 region, was investigated by examining binding of a PrP^c truncated at the N-terminus and lacking the 3F4 epitope (PrP^c-II). 25 PrP^c-II did not exhibit protease resistance after exposure to PrP^{sc}, supporting the notion that the H1 region, in which the 3F4 epitope lies, is particularly significant in PrP^c-PrP^{sc} binding (Pan et al. (1992) Protein Sci. 1:1343-1352; Haraguchi et al. (1989) Arch. Biochem. 30 Biophys. 274:1-13).

Species and detergent effect on PrP^{sc} binding to PrP^c were investigated (Example 8). When Mo 90-145 was mixed with SHaPrP^c, relatively little protease-resistant PrP^c was formed, and the addition of Sarkosyl rendered the 35 complex sensitive to proteolysis. In contrast, the

[³⁵S]PrP^c/SHaPrP^{sc} complex was resistant to proteolysis, even when exposed to up to 2% Sarkosyl for 48 h before digestion. These results are consistent with the finding that SHa 90-145 mixed with SHaPrP^c produced protease-5 resistant protein, whereas Mo 90-145 mixed with SHaPrP^c did not.

Additional attempts to disrupt the PrP^c/PrP^{sc} complexes under conditions likely to preserve the scrapie prion infectivity utilized detergents such as NP-40, 10 Tween-10, Zwittergent 3-12, and sodium deoxycholate, alone or in combination with phospholipids to form detergent-lipid-protein complexes (Gabizon et al. (1988) Proc. Natl. Acad. Sci. USA 85:6617-6621). The possibility of disrupting these complexes using the anti-15 PrP 3F4 mAb and synthetic peptides containing residues 109-122 or 90-145 was investigated. Although the mAb and peptides were added to the complexes in molar ratios of 1000:1, they were unable to dissociate the [³⁵S-]PrP^c from PrP^{sc}. Addition of a 10-fold excess of cold PrP from CHO 20 cells also failed to displace the [³⁵S-]PrP^c from the complex.

These findings provide evidence that PrP^c interacts through a domain which contains the first two putative α -helices and that a random coil configuration is required 25 for interaction.

Assays

Screening for compounds which inhibit prion protein complex formation. In one aspect, the present invention 30 provides novel assays useful in identifying inhibitors of the formation of a PrP^{sc}-like complex resulting from PrP peptide binding to PrP^c.

Although in vitro assays of the present invention can be configured in a number of ways, in a preferred 35 configuration, a test compound is contacted with PrP^c, a

PrP peptide is added to the test-compound/PrP^c mixture, and the formation of a prion protein complex detected. Detection of a prion protein complex may be accomplished in a number of ways, including by formation of an 5 insoluble complex, e.g., formation of a fibrous aggregate, of which at least 65% sediments at 100,000 x g for 1 h at 20°C, and which is at least 20% protease resistant and exhibits substantial β -sheet conformation. Percent sedimentation, protease resistance, and 10 conformation are determined by methods known in the art, such as those methods described below. Formation of a PrP^{sc}-like complex in the presence of a test compound is compared to complex formation in the absence of the test compound (control). Preferably, a test compound will 15 inhibit 20% or more complex formation relative to the control, more preferably, it will inhibit complex formation by 50% or more, and most preferably, by 75% or more.

As described above, an *E. coli* expressed PrP peptide, for example, SHa or Hu 90-231 (Fig. 1), may be 20 used in place of naturally occurring PrP^c, or in place of a synthetic peptide. The advantages of the *E. coli* produced recombinant PrP proteins include the ability to generate high levels of PrP; the ability to change the 25 sequence and length of PrP by site-directed mutagenesis of the PrP gene; absence of most post-translational modifications such as glycosylation; and ability to easily purify PrP from contaminants.

A compound identified by the assay method of the 30 invention as inhibiting complex formation can be tested in an animal model of a PrP^{sc}-mediated disease, and its ability to inhibit PrP^{sc} induction *in vivo* or treat a PrP^{sc}-mediated disease determined. Such an animal model is described in co-pending U.S. patent application Serial 35 No. 08/449,485. As defined above, treatment of a PrP^{sc}-

mediated disease includes obtaining a therapeutically detectable and beneficial effect on a patient suffering from a PrP^{Sc}-mediated disease.

The documented competition of the anti-PrP 5 monoclonal antibody 3F4 for the interaction between PrP^c and PrP^{Sc} provides an alternate strategy for an assay to screen for compounds able to block prion induction. In one embodiment, PrP^c is derivatized, e.g., with Streptavidin, and immobilized to a solid support, for 10 example, the bottom of the wells of a 96-well plate. Candidate compounds are tested for the ability to displace 3F4 from PrP^c. Binding is quantitated through standard measures, for example, by determining the amount of free antibody. Variations in this assay include use 15 of various PrP^c-like molecules from recombinant sources.

PrP^{Sc} Assay System. In one aspect, the invention features an assay for PrP^{Sc}. Since PrP^{Sc} binds tightly to PrP^c, the displacement of labelled PrP peptide from the prion protein complex can be used to assay for the 20 presence of PrP^{Sc}. In one embodiment of this method of the invention, the displacement of labelled recombinant PrP (Hu 90-231) (SEQ ID NO:10) from the prion protein complex formed between PrP^c and Hu 90-231 is used to assay for the presence of PrP^{Sc}. In the PrP^{Sc} assay method of 25 the invention, either the PrP peptide or PrP component may be labelled. Appropriate labels are known to the art, and include radioisotopes, fluorescent dyes, or spectrophotometrically-detectable chromophores.

As described above, the formation of prion protein 30 complexes composed of PrP^c/PrP peptide, PrP^c/recombinant PrP (90-231), or recombinant PrP (90-231)/PrP peptide require an excess of the second component which has a random coil and/or α -helical conformation. In a preferred embodiment of the PrP^{Sc} assay herein described, 35 the second component is labelled. Initial experiments

used a first to second component ratio of 1:5000, and subsequent optimizing experiments reduced the ratio to 1:500. Once the prion protein complex is formed, excess second component is easily removed by ultracentrifugation 5 since the prion protein complexes are insoluble. The stoichiometry of the complexes has been determined to be approximately 1:1.

The amount of displaced PrP peptide is measured after the addition of PrP^{sc}. Since PrP^c/PrP^{sc} complexes 10 are insoluble, the displaced peptide molecules are measured in the supernatant fraction after ultracentrifugation. In another embodiment, PrP^c is affinity labelled and bound to a solid phase after complex formation. When PrP^{sc} binds to the PrP^c 15 immobilized by attachment to the solid phase, the amount of displaced labelled peptides is measured in the unbound phase. Thus, the assay is calibrated by addition of known amounts of PrP^{sc}, and the amount of PrP^{sc} present in an unknown sample may be determined by the amount of 20 displaced PrP peptide.

Immobilization of PrP^c or recombinant PrP can be accomplished by methods known to the art, e.g., chemical modification using activated biotin. The biotinylated PrP^c or recombinant PrP, which has been complexed by 25 another PrP molecule such as, for example, radiolabelled SHa 90-145, is then bound to a solid phase support coated with Streptavidin (Wood & Warnke (1981) J. Histochem. Cytochem. 29:1196-1204). The addition of PrP^{sc} will displace the labelled synthetic peptide, and the amount 30 of displaced peptide will be proportional to the amount of PrP^{sc} added. Thus, measuring the amount of soluble, unbound labelled peptide provides a sensitive, rapid, and quantitative assay for PrP^{sc}.

The PrP^{sc} assay of the invention provides advantages 35 over available immunoassays in that, for example, PrP^{sc}

does not need to be soluble and PrP^c does not need to be removed prior to detection of PrP^{sc}, as required by immunodetection assays. PrP^{sc} is highly insoluble and to date, only liposomes have been found to solubilize PrP^{sc} 5 (Gabizon et al. (1987) *supra*). Thus, the PrP^{sc} assay of the present invention effectively circumvents the solubility problem presented by PrP^{sc}. The assay may be optimized for detection of PrP^{sc} contained in human, bovine, ovine, or porcine prions.

10 Design of transgenes for bioassays of prions in mice. The above described PrP^{sc} assay may also be used in designing transgenes for more rapid and sensitive bioassays for prions.

15 The central region of PrP delimited by codons 96-169 appears to be the region where PrP^c and PrP^{sc} interact when a complex between the two molecules is formed (Telling et al. (1995) *Cell* 83:79-90). The prion protein complexes formed between PrP^c/PrP peptide, PrP^c/recombinant PrP, or recombinant PrP/PrP peptide can be used to define 20 interactions between PrP^c and PrP^{sc} which are more sensitive than the naturally occurring one studied to date. Changing the sequence of the first component of the complex may identify residues which permit tighter bonding of the non-homologous second component. Once 25 such sequences are defined, the transgenic expressing such modified PrP^c molecules may be inoculated with prions and the incubation times measured.

30 In one embodiment, intermediate screening may be used employing the yeast two hybrid system. The study of interacting PrP molecules can be rapidly performed with the yeast two hybrid system, e.g., one of the PrP genes is mutagenized and screened for increased interactions, as described by Chien et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:9578-9582. Once such clones are identified, 35 synthetic peptides or recombinant PrP molecules are

produced and evaluated for prion protein complex formation. When prion protein complexes are avidly formed, transgenes with those sequences are constructed for micro-injection to produce transgenic mice by methods 5 known in the art.

The affinity of the second component for the first is assessed by the concentration of the second component required to form prion protein complexes. Once sequences are identified that lower the concentration of the second 10 component required for prion protein complex formation, the affinity of the second component for the first component is measured by, for example, surface plasmon resonance (Fagerstam et al. (1990) *J. Mol. Recognit.* 3:208-214; Stenberg et al. (1991) *J. Colloid Interface Sci.* 143:513-526; Liedberg & Lundstrom (1993) *Sensors Actuators B* 11:63-72). The first component is immobilized on a gold film and the second component is then bound. The binding of the second component is detectable as a change in the refractive index.

20 The method of the invention is optimized for transgenes for bioassay of human, bovine, ovine, and porcine prions. This approach has important implications for construction of a universal transgene for bioassay of human prions. As recently described in work from this 25 laboratory, amino acid mismatches at residues 102 and 129, but not 200, result in substantial prolongation of the incubation time required for onset of PrP-mediated disease (Telling et al. (1995) *supra*). Identifying amino acid side chains at these and other critical residues 30 that will permit transmission of all human prions without regard to the amino acid sequence of PrP^{sc} may be accomplished with the above described assay methodology. In addition to developing a universal transgene with respect to the sequence of PrP^{sc}, the above described 35 approach may be utilized to create an artificial PrP^c

which interacts with human PrP^{Sc} more efficiently than naturally occurring human PrP^C itself. Thus, a more sensitive and rapid bioassay for human prions may be developed with the use of the invention.

5

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and 10 use the assays of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, 15 temperatures, etc.) but some experimental error and deviations should be accounted for. Unless otherwise indicated, temperature is in degrees Centigrade, molecular weight is average molecular weight, and pressure is at or near atmospheric.

20 Example 1. Materials and Methods

SHaPrP was subcloned into the glutamine synthetase expression vector, pEE 12 (Cell/Tech, Alameda, CA). Chinese hamster ovary (CHO)K1 cells (ATCC) were seeded at 10⁶ cells per 10 cm dish in GMEM-S medium containing 10% 25 dialyzed fetal calf serum (FCS) (Gibco-BRL) (Bebbington & Hentschel (1987) in: DNA Cloning: A Practical Approach (Glover, D.M., ed.); IRL Press, Oxford, pp. 163-188). Cells were transfected with 10 µg of pEE 12-SHaPrP vector 30 per dish using the CaPO₄ method (Gorman (1985) in DNA Cloning: A Practical Approach supra, pp. 143-190). After growing cells in 25 µM methionine sulfoximine (MSX) (Sigma) for 2 weeks, 60 clones were randomly selected, and grown in 100, 200, or 400 µM MSX. The 35 clones were analyzed by Western blot to identify the highest expressors (Towbin et al. (1979) Proc. Natl.

Acad. Sci. USA 76:4350-4354). From clone #30C1, phosphatidylinositol-specific phospholipase C (PIPLC) digestion released ~90 ng SHaPrP^c from 10⁶ cells (Koke et al. (1991) Protein Expr. Purif. 2:51-58).

5 A recombinant PrP of 142 amino acids corresponding to Syrian hamster (SHa) PrP residues 90-231 (SEQ ID NO:2) was expressed at high levels in *E. coli* and purified to homogeneity under renaturing conditions.

The CHO cells expressing SHaPrP^c were metabolically 10 radiolabeled with [³⁵S-]Met (100 μ Ci/ml, NEN) (Borchelt et al. (1990) J. Cell Biol. 110:743-752), and immunoaffinity purified (Pan et al. (1992) Protein Sci. 1:1343-1352) from lysates using the anti-PrP 3F4 monoclonal antibody (mAb) (Kascak et al. (1987) J. Virol. 61:3688-3693) 15 which recognizes SHaPrP residues 109-112 (Rogers et al. (1991) J. Immunol. 147:3568-3574). SHaPrP^c was eluted from mAb/protein A Sepharose with 3 M guanidine hydrochloride (Gdn-HCl), centrifuged at 16,000 \times g for 2 min at 4°C, and the supernatant diluted 1:10 in TN buffer 20 (130 mM NaCl, 10 mM Tris-HCl, pH 7.4); in some cases, PrP^c was precipitated with 4 volumes of methanol to separate it from the Gdn-HCl and residual detergent. [³⁵S-]PrP^c concentrations were determined by comparison with signals from Western blots with known quantities of PrP^c from SHa 25 brain, and by measurements in a scintillation spectrometer.

Syrian hamsters (Lak:LVG) obtained from Charles River Laboratories were inoculated with Sc237 prions (Marsh & Kimberlin (1975) J. Infect. Dis. 131:104-110) 30 and sacrificed when they showed signs of CNS dysfunction. SHaPrP^{sc} was purified from the brains of these ill animals according to the method of Turk et al. (1988) Eur. J. Biochem. 176:21-30, herein specifically incorporated by reference). Similarly, mouse (Mo) PrP^{sc} was purified from 35 the brains of ill mice inoculated with RML prions

(Chandler (1961) Lancet 1:1378-1379). SHaPrP^c was purified from the brains of uninoculated adult SHa (Pan et al. (1993) Proc. Natl. Acad. Sci. USA 90:10962-10966, herein specifically incorporated by reference) and 5 radioiodinated with [¹²⁵I] (1 mCi/50 µg PrP^c, Amersham) using Iodo-Beads (Pierce) according to the method of Lee & Griffiths (1984) J. Immunol. Methods 74:181-189, herein specifically incorporated by reference).

PrP peptides were synthesized and purified as 10 described (Gasset et al. (1992) supra; Nguyen et al. (1995) supra); conformations were established by FTIR spectroscopy and CD, as described previously (Nguyen et al. (1995) Biochemistry 34:4186-4192 and Zhang et al. (1995) J. Mol. Biol. 250:514-526, both of which 15 references are herein specifically incorporated by reference). The PrP peptides used in the experiment are identified in Table 1. The PrP peptides were synthesized from N-Fmoc-protected amino acids using either an Applied Biosystems (Foster City, CA) Model 430 automated 20 synthesizer or a Millipore (Bedford, MA) Model 9050 Plus PepSynthesizer and purified by RP-HPLC, as described in Nguyen et al. (1995) supra.

FTIR measurements were made by transmission 25 spectroscopy using a Perkin Elmer (Norwalk, CT) System 2000 spectrometer equipped with a microscope attachment and purged with dry nitrogen. CD spectra were recorded on a Jasco Model 720 spectropolarimeter using 0.01 cm path length cylindrical quartz cells at room temperature. Peptide concentrations are as described in Nguyen et al. 30 (1995) supra. Proteinase K (Gibco-BRL) was used at a concentration of 50 µg/ml and incubated for 1 h at 37°C. Although PrP^c was digested in 3 M Gdn-HCl, the activity of proteinase K was reduced ~90% as measured by a colorimetric assay with carbobenzoxy-valyl-glycyl- 35 arginine- ρ -nitroanilide (Boerhinger Mannheim).

Digestions with proteinase K were terminated by addition of 1 mM (4-amidinophenyl) methanesulfonyl fluoride (PMSF) (Boehringer Mannheim). SDS-PAGE was performed according to Laemmli (Laemmli (1970) *Nature* 227:680-685), and 5 autoradiograms obtained. Immunoblots were formed using the ECL system (Amersham) with anti-PrP 3F4 mAb. Using a JEOL 100CX electron microscope, samples were viewed at 80 Kev after negative staining.

50 ng of [³⁵S-]SHaPrP^c at a concentration of ~10 µg/ml 10 were incubated in Eppendorf microfuge tubes with TN buffer for up to 48 h at 37°C. PrP peptides were mixed with immunopurified, radiolabeled PrP^c in 0.3 M Gdn-HCl at molar ratios ranging from 50:1 to 5000:1. Anti-PrP 3F4 mAb and 13A5 mAb (Barry & Prusiner (1986) supra) were 15 added to SHaPrP^c in molar ratios ranging from 1:1 to 50:1. 3F4 and 13A5 are mouse monoclonal antibodies which recognize amino acid residues 109-112 and 138-141, respectively, of the SHa PrP proteins (Rogers et al. (1991) *J. Immunol.* 147:33568-3574, herein specifically 20 incorporated by reference). The PrP^{sc} (~1 mg/ml) was pretreated with Gdn-HCl at concentrations ranging from 0 to 6 M for 16 h at 37°C. Upon termination of the incubation, an equal volume of TN buffer was added to all samples and analysis performed immediately.

25

Example 2. Promotion of Formation of Protease-Resistant PrP by PrP Peptides.

[³⁵S-]SHaPrP^c was incubated with a synthetic peptide or PrP^{sc}. The synthetic peptides were as follows: random 30 coil SHa 90-145 at peptide to PrP^c ratios of 50:1, 500:1, or 5000:1; β -sheet SHa 90-145 at ratios of 50:1, 500:1, or 5000:1; random coil Mo 90-145 at a ratio of 5000:1; β -sheet Mo 90-145 at a ratio of 5000:1; β -sheet SHa 109-122 (H1) at a ratio of 5000:1; random coil SHa 104-122 35 (104H1) at a ratio of 5000:1; random coil SHa 109-141;

random coil SHa 90-145(A117V) at a ratio of 5000:1. In some experiments, *E. coli* expressed SHa 90-231 was used in place of PrP^c. SHa 90-231 was mixed with the synthetic peptide SHa 90-145 under the same conditions described 5 above. Incubations were performed as described in Example 1, in TN buffer containing 0.3 M Gdn-HCl for 48 h at 37°C. Samples were digested with proteinase K for 1 h at 37°C, followed by SDS-PAGE and autoradiography. SDS-PAGE included undigested PrP^c and SHaPrP^{sc}.

10 Results. Random coil SHa 90-145 incubated at a ratio of 5000:1 induced protease resistance, while SHa 90-145 in the β -sheet form did not. Mo 90-145 in either the random coil or β -sheet form did not induce protease resistance when incubated with SHaPrP^c. Neither H1 15 (containing residues 109-122) nor a longer version composed of residues 104-122 (104H1) induced protease resistance in PrP^c. SHa 109-141 and SHa 90-145 both induced protease resistance. The most efficient formation of protease-resistance radiolabeled PrP^c was 20 seen with the SHa 90-145(A117V) peptide in which alanine is replaced with alanine at position 117. Compared with the wild-type peptide, only 30-40% of the mutant peptide was needed to produce equivalent amounts of protease-resistant PrP^c. The addition of detergent (2% (w/v) 25 Sarkosyl) disrupted the PrP^c/PrP peptide complexes and rendered the PrP^c sensitive to protease activity. With SHa 90-145(A117V), about 30% of the [³⁵S-]PrP^c/PrP peptide complex exhibited protease resistance; with SHa 90-145, only 10-15% was resistant.

30 When SHa 90-145 was mixed with SHa 90-231, a complex formed which was insoluble and protease resistant.

Example 3. Solubility Characteristics of PrP^c/PrP Peptide Complexes.

SHaPrP^c was incubated alone or with SHa 90-145 (A117V) in TN buffer containing 0.3 M Gdn-HCl for 48 h; samples 5 were centrifuged at 100,000 x g for 1 h at 20°C, and the pellets resuspended in TN buffer. The sedimented pellet was examined by FTIR spectroscopy, CD, and electron microscopy (EM) as described in Zhang et al. (1995) supra. Specimens stained with 2% uranyl acetate or 2% 10 ammonium molybdate.

Results. Less than 10% of the [³⁵S-]PrP^c sedimented when SHaPrP^c was incubated alone. With the addition of SHa 90-145 (A117V), ~65% of the radiolabel pelleted. FTIR spectroscopy of the sedimented PrP^c/SHa 90-145 complex 15 showed a substantial increase in β -sheet content compared to pelleted PrP^c. As measured by CD, the supernatant containing primarily unbound SHa 90-145 peptide remained in random coil form, as did the peptide incubated alone in TN buffer for 48 h.

20 When examined by electron microscopy, PrP^c pellets incubated alone showed many spherical aggregates up to 20 nm in diameter. In contrast, numerous large, filamentous polymers were found in the pellets of the PrP^c/PrP peptide mixture.

25

Example 4. Anti-PrP Monoclonal Antibody Binding to PrP^c.

[³⁵S-]PrP^c was incubated for 48 h with either SHa 90-145 peptide or SHaPrP^{sc} in the presence or absence of α -PrP 3F4 or 13A5 mAbs. Samples were digested with 30 proteinase K for 1 h at 37°C followed by SDS-PAGE and autoradiographed. SHa 90-145 was incubated with PrP^c at a ratio of 5000:1 (peptide to PrP) without and with mAb 3F4 (mAb:PrP^c of 50:1) or mAb 13A5 (500:1). Both 3F4 and 13A5 mAbs prevented formation of protease-resistant 35 PrP^c/PrP peptide complexes.

Example 5. Spontaneous Formation of Protease-Resistant PrP.

Immunopurified PrP^c (10 µg/ml) from CHO cells ([³⁵S]SHaPrP^c) transfected as described in Example 1 and 5 PrP^c (1 mg/ml) from SHa brain were incubated for 0 min, 2 min, or 48 h at 37°C in the presence of 0.75 M Gdn-HCl. Prior to digestion with proteinase K for 1 h at 37°C, samples were diluted 1:4 with TN buffer. Samples were then digested with proteinase K and analyzed by SDS-PAGE 10 and Western blotting using the anti-PrP 3F4 mAb.

Results. Approximately 1% of the PrP^c was found to be protease resistant after 48 h under these conditions, compared to ~30% of the PrP^c that was rendered resistant with the SHa 90-145 (A117V) peptide. PrP^c overexpressed in 15 CHO exhibited a broad size range, presumably due to hyperglycosylation in contrast to PrP^c from SHa brain. To confirm the identity of the protease-resistant band, the blot was autoradiographed; after 4 weeks exposure, faint but discrete bands of identical size were detected in 20 lanes containing ³⁵S-PrP^c. The addition of 0.2% Sarkosyl rendered the "protease-resistant" PrP^c sensitive to proteolytic digestion.

Example 6. Effect of PrP^{sc} Denaturation With Gdn-HCl.

25 SHaPrP^{sc} was incubated with 0, 3 M, or 6 M Gdn-HCl for 0 min, 2 min, or 48 h at 37°C followed by digestion with proteinase K for 1 h. Samples were analyzed by SDS-PAGE and Western blotting using the anti-PrP 3F4 mAb.

Results. When PrP^{sc} (denatured in 3 M Gdn-HCl, then 30 diluted in buffer to a final concentration of 0.3 - 2 M Gdn-HCl) was mixed with PrP^c, no protease-resistant [³⁵S-]PrP^c was produced. However, as shown in Example 2, mixing undenatured PrP^{sc} with PrP^c did produce protease-resistant [³⁵S-]PrP^c. A 10-fold excess of PrP^{sc} was 35 insufficient to produce protease-resistant [³⁵S-]PrP^c; a

50-fold excess of PrP^{Sc} was required. The presence of 0.3 M Gdn-HCl in the reaction mixture seemed to be essential since its removal by methanol precipitation prior to mixing prevented complex formation. About 50% of the 5 [³⁵S-]PrP^C was recovered in complexes sedimented at 100,000 x g for 1 h, of which 10-15% were protease resistant.

Example 7. Anti-PrP Monoclonal Antibody Prevents Binding of PrP^{Sc} to PrP^C.

10 [³⁵S-]PrP^C was incubated for 48 h with either SHa 90-145 peptide or SHaPrP^{Sc} in the presence or absence of anti-PrP 3F4 or 13A5 in a mAb/PrP^C ratio of 500:1, and the formation of a PrP^C/PrP^{Sc} complex determined as described above. The interaction between PrP^C and PrP^{Sc} was found 15 to be inhibited by the anti-PrP mAb 3F4, but not 13A5.

A PrP^C peptide truncated at the N-terminus and lacking the 3F4 epitope, PrP^C-II, was incubated with PrP^{Sc}, and the formation of protease resistance determined. PrP^C-II did not exhibit protease resistance.

20 Example 8. Effect of Detergent on SHaPrP^C Incubated with MoPrP^{Sc} or SHaPrP^{Sc}.

[³⁵S-]SHaPrP^C was incubated for 48 h with unlabeled MoPrP^{Sc} or SHaPrP^{Sc} in the absence or presence of 0.2%, 1%, 25 or 2% Sarkosyl. Samples were analyzed by SDS-PAGE and Western blotting using the anti-PrP 3F4.

Results. When MoPrP^{Sc} was mixed with SHaPrP^C, relatively little protease-resistant PrP^C was formed, and the addition of Sarkosyl rendered the complex sensitive 30 to proteolysis. In contrast, the [³⁵S-]PrP^C/SHaPrP^{Sc} complex was resistant to proteolysis, even when exposed with up to 2% Sarkosyl for 48 h prior to digestion.

Table 1. PrP Peptides

PrP Peptide	Residues	Sequence	SEQ ID NO
Sha 90-145	90-145	GQGGGTHNQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPMM HFGNDW	1
Sha 90-231	90-231	GQGGGTHNQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPMM HFGNDWEDRYRENMNRYPNQVYYRPVVDQYNNNQNNFVHDCVNITIKQHTV TTTTKGENFTETDIKIMERVVQEMCTTQYQKESQAYYDGRRS	2
H1	109-122		3
H1 (Mo)	108-121		4
104H1	104-122	MKHMAGAAAAGAVV	5
H2	129-141	LKHVAGAAAAGAVV	6
Sha 109-141	109-141	KPKTNMKHMAGAAAAGAVV	5
Sha 90-145 (A117V)	90-145	MLGSAMSRPMMHF	6
Mo 90-145	90-145	MKHMAGAAAAGADDGGLGGYMLGSAMSRPMMHE	7
		GQGGGTHNQWNKPSKPKTNMKHMAGAATAGAVVGGLGGYMLGSAMSRPMM HFGNDWGAADAG	8
		GQGGGTHNQWNKPSKPKTNLKHYAGAAAAGAVVGGLGGYMLGSAMSRPMM HFGNDW	9

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: The Regents of the University of California
- (ii) TITLE OF INVENTION: Formation and use of prion protein (PrP) complexes.
- (iii) NUMBER OF SEQUENCES: 10

(iv) CORRESPONDENCE ADDRESS:

- (A) ADDRESSEE: Robbins, Berliner & Carson
- (B) STREET: 201 N. Figueroa Street, 5th Floor
- (C) CITY: Los Angeles
- (D) STATE: California
- (E) COUNTRY: USA
- (F) ZIP: 90012-2628

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: ASCII

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Berliner, Robert
- (B) REGISTRATION NUMBER: 20,121
- (C) REFERENCE/DOCKET NUMBER: 5555-418

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (213) 977-1001
- (B) TELEFAX: (213) 977-1003

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Gly Gln Gly Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro
 5 10 15

Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Ala Gly Ala Val
 20 25 30

Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro
 35 40 45

Met Met His Phe Gly Asn Asp Trp
 50 55

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 142 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Gln Gly Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro
 5 10 15

Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Ala Gly Ala Val
 20 25 30

Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro
 35 40 45

Met Met His Phe Gly Asn Asp Trp Glu Asp Arg Tyr Tyr Arg Glu Asn
 50 55 60

Met Asn Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Val Asp Gln Tyr
 65 70 75 80

Asn Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys
 85 90 95

Gln His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr
 100 105 110

Asp Ile Lys Ile Met Glu Arg Val Val Glu Gln Met Cys Thr Thr Gln
 115 120 125

Tyr Gln Lys Glu Ser Gln Ala Tyr Tyr Asp Gly Arg Arg Ser
 130 135 140

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Lys His Met Ala Gly Ala Ala Ala Ala Gly Ala Val Val
 5 10

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Leu Lys His Val Ala Gly Ala Ala Ala Ala Gly Ala Val Val
 5 10

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Lys Pro Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Ala Gly
 5 10 16

Ala Val Val
 19

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Leu Gly Ser Ala Met Ser Arg Pro Met Met His Phe
 5 10

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 3 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
 Met Lys His Met Ala Gly Ala Ala Ala Gly Ala Asp Asp Gly Gly
 5 10 15
 Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro Met Met His
 20 25 30

Glu
 33

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 62 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
 Gly Gln Gly Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro
 5 10 15

Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Thr Ala Gly Ala Val
 20 25 30

Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro
 35 40 45

Met Met His Phe Gly Asn Asp Trp Gly Ala Ala Asp Ala Gly
 50 55 60 62

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 56 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
 Gly Gln Gly Gly Gly Thr His Asn Gln Trp Asn Lys Pro Ser Lys Pro
 5 10 15

Lys Thr Asn Leu Lys His Tyr Ala Gly Ala Ala Ala Gly Ala Val
 20 25 30

Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro
 35 40 45

Met Ile His Phe Gly Asn Asp Trp
 50 55

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 142 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Gly Gln Gly Gly Gly Thr His Ser Gln Trp Asn Lys Pro Ser Lys Pro
 5 10 15

Lys Thr Asn Met Lys His Met Ala Gly Ala Ala Ala Gly Ala Val
 20 25 30

Val Gly Gly Leu Gly Gly Tyr Met Leu Gly Ser Ala Met Ser Arg Pro
 35 40 45

Ile Ile His Phe Gly Ser Asp Tyr Glu Asp Arg Tyr Tyr Arg Glu Asn
 50 55 60

Met His Arg Tyr Pro Asn Gln Val Tyr Tyr Arg Pro Met Asp Glu Tyr
 65 70 75 80

Ser Asn Gln Asn Asn Phe Val His Asp Cys Val Asn Ile Thr Ile Lys
85 90 95

Gln His Thr Val Thr Thr Thr Lys Gly Glu Asn Phe Thr Glu Thr
100 105 110

Asp Val Lys Met Met Glu Arg Val Val Glu Gln Met Cys Ile Thr Gln
115 120 125

Tyr Glu Arg Glu Ser Gln Ala Tyr Tyr Gln Arg Gly Ser Ser
130 135 140

CLAIMS

1. A prion protein (PrP) peptide characterized by an ability to induce a conformational change in cellular prion protein (PrP^c).

5 2. The PrP peptide of claim 1, wherein said conformational change provides enhanced insolubility relative to PrP^c.

10 3. The PrP peptide of claim 1, wherein said conformational change is an increase in β -sheet conformation relative to PrP^c.

4. The PrP peptide of claim 3, wherein said β -sheet formation is about 30% to 100% greater than that of the PrP^c.

15 5. The PrP peptide of claim 3, wherein said β -sheet formation is about 50% to 100% greater than that of the PrP^c.

6. The PrP peptide of claim 1, wherein said conformational change provides increased protease resistance relative to PrP^c.

20 7. The PrP peptide of claim 6, wherein said conformational change is the formation of a complex having about 20% to about 100% protease resistant.

25 8. The PrP peptide of claim 6, wherein said conformational change is the formation of a complex having about 45% to about 100% protease resistant.

9. The PrP peptide of claim 6, wherein said conformational change is the formation of a complex having about 60% to about 100% protease resistant.

10. The PrP peptide of claim 1, wherein said 5 peptides are characterized by a configuration selected from the group consisting of an α -helical domain and a random coil in an aqueous solution.

11. The PrP peptide of claim 1, having an amino acid sequence

10 (a) selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10; and

15 (b) amino acid sequences substantially similar to the sequences of (a), wherein said substantially similar amino acid sequences bind PrP^c to form a complex.

12. The PrP peptide of claim 1, wherein said PrP^c is selected from the group consisting of human PrP^c, hamster PrP^c, mouse PrP^c, bovine PrP^c, and ovine PrP^c.

20 13. The PrP peptide of claim 8, wherein said PrP^c is human PrP^c.

14. A method for screening compounds which inhibit the binding of PrP^c to a PrP peptide, comprising the steps of:

25 (a) contacting a test compound with a first component PrP^c in the presence of a second component PrP peptide, wherein the first and second components form a prion protein complex; and

(b) detecting formation of a prion protein complex.

15. The method of claim 14, wherein the prion protein complex has increased insolubility relative to PrP^c.

16. The method of claim 15, wherein said complex 5 has increased β -sheet conformation relative to the first component PrP^c.

17. The method of claim 14, wherein said first component PrP^c is selected from the group consisting of human PrP^c, hamster PrP^c, mouse PrP^c, bovine PrP^c, and 10 ovine PrP^c.

18. The method of claim 17, wherein said PrP^c is human PrP^c.

19. The method of claim 14, wherein said first component PrP^c is the peptide having the amino acid 15 sequence of SEQ ID NO:10.

20. The method of claim 14, wherein said second component is one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

21. A method for screening compounds which inhibit 20 induction of a prion protein complex, comprising the steps of:

(a) contacting a test compound with a first component PrP^c in the presence of a second component PrP 25 peptide; and

(b) detecting induction of the prion protein complex.

22. The method of claim 21, wherein said prion protein complex has increased insolubility relative to PrP^c.

23. The method of claim 21, wherein said first 5 component PrP^c is selected from the group consisting of human PrP^c, hamster PrP^c, mouse PrP^c, bovine PrP^c, and ovine PrP^c.

24. The method of claim 23, wherein said PrP^c is human PrP^c.

10 25. The method of claim 21, wherein said first component PrP^c is the peptide having the amino acid sequence of SEQ ID NO:10.

15 26. The method of claim 21, wherein said second component is one of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10.

20 27. An assay methodology, comprising:
providing a PrP^c protein;
contacting the PrP^c protein with a test compound;
combining a peptide with the PrP^c protein which peptide is characterized by causing the PrP^c protein to undergo conformational changes including the formation of β -sheets in the absence of the test compound; and
determining the effect of the test compound on
25 preventing the conformational changes.

28. The assay methodology of claim 27, wherein conformational changes result in increased insolubility as compared to PrP^c.

29. The assay methodology of claim 27, wherein conformational changes result in increased protease resistance as compared to PrP^c.

30. The assay methodology of claim 27, wherein PrP^c 5 is selected from the group consisting of human PrP^c, hamster PrP^c, mouse PrP^c, bovine PrP^c, and ovine PrP^c.

31. The assay methodology of claim 30, wherein PrP^c is human PrP^c.

32. The assay methodology of claim 27, wherein PrP^c 10 is a human variant of PrP^c.

33. An assay for PrP^{sc}, said assay comprising the steps of:

(a) mixing a first component PrP^c and a second component PrP peptide under conditions in which a prion 15 protein complex is formed;

(b) adding a test sample suspected of containing PrP^{sc};

(c) measuring the amount of PrP peptide displaced 20 from the prion protein complex by formation of PrP^c/PrP^{sc} complexes,

wherein the amount of PrP peptide displaced from the prion protein complex is proportional to the amount of PrP^{sc} present in the test sample.

34. The method of claim 33, wherein the second 25 component PrP peptide is labelled and the amount of PrP peptide displaced from the prion protein complex is measured by removing the PrP^c/PrP^{sc} complex and determining the amount of label remaining.

35. The method of claim 33, wherein the first component PrP^c is immobilized by attachment to a solid phase, and the amount of displaced labelled PrP peptide is measured in the unbound phase.

5 36. The method of claim 34, wherein the PrP peptide is labelled with a radioactive isotope, a fluorescent dye, or a chromophore.

Fig. 1. Syrian Hamster (Sha) and Human (Hu) 90-231 PrP^C Sequence

90	100	110	120	130	140	150
Sha: G QGGGTHNQWN	KPSKP K TN M K	HMAGAAAAGA	VVGGGLGGYML	GSAMS R FMMH	FGNDWEDRYY	
Hu: G QGGGTH S QWN	KPSKP K TN M K	HMAGAAAAGA	VVGGGLGGYML	GSAMS R PIIH	FGSDYEDRYY	
160	170	180	190	200	210	
Sha: RENMNRYPNQ	VYYRPV D QYN	NQNNFVHDCV	NITIKQHTVT	TTTKGENFTE	TDIKIMERVV	
Hu: RENM H RYPNQ	VYYRP M DEYS	NQNNFVHDCV	NITIKQHTVT	TTTKGENFTE	TDV K MMERVV	
220	230	231				
Sha: EQMCTTOYQK	ESQAYYD G RR	S				
Hu: EQMC I TQYER	ESQAYY Q RG S	S				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/17462

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL : 435/7.1, 69.1, 240.2; 436/518; 514/26.1; 530/350, 388.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 69.1, 240.2; 436/518; 514/26.1; 530/350, 388.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAN et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Science USA. December 1993, Vol. 90, pages 10962-10966, especially page 10962.	1-12 —
Y	KRETZSCHMAR et al. Molecular cloning of a human prion protein cDNA. DNA. 1986, Vol. 5, No. 4, pages 315-324, especially 315, 316, and 319.	13-26
Y		13

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	
•A• document defining the general state of the art which is not considered to be of particular relevance	•T• later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•E• earlier document published on or after the international filing date	•X• document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L• document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	•Y• document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O• document referring to an oral disclosure, use, exhibition or other means	•Z• document member of the same patent family
•P• document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

31 JANUARY 1997

Date of mailing of the international search report

19 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THERESA KING

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/17462

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CAUGHEY et al. Scrapie-associated PrP accumulation and its inhibition: Revisiting the amyloid-glycosaminoglycan connection. Annals of the New York Academy of Science. 06 June 1994. Vol. 724, pages 290-295, entire article.	14-26
Y	US 5,565,186 A (PRUSINER et al.) 15 October 1996, column 27-30.	14-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/17462

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

G01N 33/53, 33/543; C12P 21/06; C12N 5/00; A01N 45/00; C07K 1/00, 16/00

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

HCAPLUS, WPIDS, BIOSIS, MEDLINE, EMBASE, APS, SEQUENCE DATA BASE(A-GENESEQ24)
Search terms: PrP, prion protein peptide, complex, scrapie, spongiform, kuru, Creutzfeldt-Jakob, Gerstmann, slow
virus, fatal insomnia, prion disease, screen